DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype

Biomarkers

Volumn 18, Issue 6, 2013, Pages 516-524

  De Vriendt, Veerle ^a   De Roock, Wendy ^b   Di Narzo, Antonio Fabio ^c   Tian, Sun ^d   Biesmans, Bart ^a   Jacobs, Bart ^a   Budinska, Eva ^e   Sagaert, Xavier ^f   Rossi, Simona ^c   D'Ario, Giovanni ^c   Delorenzi, Mauro ^c,f   Simon, Iris ^d   Vecchione, Loredana ^a   Tejpar, Sabine ^a,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d Agendia NV   (Netherlands)

^e MASARYK UNIVERSITY   (Czech Republic)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Colorectal cancer; gene expression; MAPK pathway

Indexed keywords

B RAF KINASE; CETUXIMAB; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; DUAL SPECIFICITY PHOSPHATASE 6; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DUAL SPECIFICITY PHOSPHATASE 6; DUAL-SPECIFICITY PHOSPHATASES; ENZYME ACTIVATION; GENOTYPE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MITOGEN-ACTIVATED PROTEIN KINASES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885204398     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.819038     Document Type: Article

References (41)

1. Adjei AA, Cohen RB, Franklin W, et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogenactivated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY- 142886) in patients with advanced cancers. J Clin Oncol 26:2139-46.
2. Amit I, Citri A, Shay T, et al. (2007). A module of negative feedback regulators defines growth factor signaling. Nat Genet 39:503-12.
3. Baker JB, Dutta D, Watson D, et al. (2011). Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104:488-95.
4. Balko JM, Cook RS, Vaught DB, et al. (2012). Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18:1052-9.
5. Bild AH, Yao G, Chang JT, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-7.
6. Bildstein L, Pili B, Marsaud V, et al. (2011). Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Eur J Pharm Biopharm 79:612-20.
7. Budinska E, Popovici V, Tejpar S, et al. (2013). Gene expression patterns unveil a new level of 388 molecular heterogeneity in colorectal cancer. J Pathol. doi: 10.1002/path.4212.
8. Cadalbert LC, Sloss CM, Cunningham MR, et al. (2010). Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. Cell Signal 22:357-65.
9. Chu Y, Solski PA, Khosravi-Far R, et al. (1996). The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271:6497-501.
10. De Roock W, Claes B, Bernasconi D, et al. (2010a). Effects of Kras, Braf, Nras, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753-62.
11. De Roock W, Jonker DJ, Di Nicolantonio F, et al. (2010b). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy- refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-20.
12. De Roock W, Piessevaux H, De Schutter J, et al. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-15.
13. Dry JR, Pavey S, Pratilas CA, et al. (2010). Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70:2264-73.
14. Groom LA, Sneddon AA, Alessi DR, et al. (1996). Differential regulation of the Map, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J 15:3621-32.
15. Groschl B, Bettstetter M, Giedl C, et al. (2012). Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer 132:1537-46.
16. Hou MF, Chang CW, Chen FM, et al. (2012). Decreased total MKP-1 protein levels predict poor prognosis in breast cancer. World J Surg 36:1922-32.
17. Irahara N, Baba Y, Nosho K, et al. (2010). NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19:157-63.
18. Jeffrey KL, Camps M, Rommel C, Mackay CR. (2007). Targeting dualspecificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6:391-403.
19. Jing J, Greshock J, Holbrook JD, et al. (2012). Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720-9.
20. Lawan A, Al-Harthi S, Cadalbert L, et al. (2011). Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential nonredundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J Biol Chem 286:12933-43.
21. Lea IA, Jackson MA, Dunnick JK. (2009). Genetic pathways to colorectal cancer. Mutat Res 670:96-8.
22. Li HT, Lu YY, An YX, et al. (2011). Kras, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 25:1691-7.
23. Messersmith WA, Falchook GS, Fecher LA, et al. (2011). Clinical activity of the oral MEK1/2 inhibitor GSK1120212 in pancreatic and colorectal cancer. J Clin Oncol 29(suppl 4):abstr 246 (Gastrointestinal Cancers Symposium 2011, San Francisco, CA, USA).
24. Miyake M, Takemasa I, Matoba R, et al. (2011). Heterogeneity of colorectal cancers and extraction of discriminator gene signatures for personalized prediction of prognosis. Int J Oncol 39:781-9.
25. Muda M, Boschert U, Dickinson R, et al. (1996a). MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J Biol Chem 271: 4319-26.
26. Muda M, Theodosiou A, Rodrigues N, et al. (1996b). The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J Biol Chem 271:27205-8.
27. Normanno N, Tejpar S, Morgillo F, et al. (2009). Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6:519-27.
28. Nunes-Xavier CE, Tarrega C, Cejudo-Marin R, et al. (2010). Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester. J Biol Chem 285:26417-30.
29. Patterson KI, Brummer T, O'brien PM, Daly RJ. (2009). Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475-89.
30. Popovici V, Budinska E, Tejpar S, et al. (2012). Identification of a poorprognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 30:1288-95.
31. Prenen H, De Schutter J, Jacobs B, et al. (2009). PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15:3184-8.
32. Rinehart J, Adjei AA, Lorusso PM, et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-62.
33. Roth AD, Tejpar S, Delorenzi M, et al. (2010). Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-74.
34. Salazar R, Roepman P, Capella G, et al. (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29:17-24.
35. Schlicker A, Beran G, Chresta CM, et al. (2012). Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 5:66-81.
36. Tentler JJ, Nallapareddy S, Tan AC, et al. (2010). Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 9: 3351-62.
37. Tian S, Simon I, Moreno V, et al. (2012). A combined oncogenic pathway signature of Braf, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62:540-9.
38. Van Cutsem E, Labianca R, Bodoky G, et al. (2009). Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-25.
39. Vaughn CP, Zobell SD, Furtado LV, et al. (2011). Frequency of Kras, Braf, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50:307-12.
40. Wu S, Wang Y, Sun L, et al. (2011). Decreased expression of dualspecificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer 11:413-21.
41. Zhang Z, Kobayashi S, Borczuk AC, et al. (2010). Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31:577-86.